Clinical & Pharma

CARD Clinic's Battle for Survival in Libby's Asbestos Crisis
Clinical & Pharma CARD Clinic's Battle for Survival in Libby's Asbestos Crisis

A small town in the shadow of environmental history, Libby, Montana, has been dealing with asbestos contamination's relentless grip. The crisis began due to the operations of a sprawling vermiculite mine beginning in the 20th century, and now Libby faces dire health consequences traced back to

Is Vaccine Policy Distorting Science Under Kennedy’s HHS?
Clinical & Pharma Is Vaccine Policy Distorting Science Under Kennedy’s HHS?

The Department of Health and Human Services (HHS), under Secretary Robert F. Kennedy Jr., has sparked a profound debate by revising U.S. COVID-19 vaccination guidelines in a controversial manner. Kennedy's policy decisions, particularly the removal of vaccine recommendations for pregnant women

Can CDC's Crisis Undermine HIV Research Progress?
Clinical & Pharma Can CDC's Crisis Undermine HIV Research Progress?

The Centers for Disease Control and Prevention (CDC) has recently faced considerable disruption, raising alarm and uncertainty across the spectrum of ongoing HIV research initiatives. The upheaval started with abrupt layoffs of several key HIV specialists, only to be followed by sudden

NIH Workers Protest Against Administration's Policy Cuts
Clinical & Pharma NIH Workers Protest Against Administration's Policy Cuts

Hundreds of employees at the National Institutes of Health (NIH) have openly protested against recent policy changes enacted by the current administration. These alterations, which threaten to undermine the NIH's standing as a leading public funder of biomedical research, have spurred

Is RFK Jr. Spreading Misinformation on COVID-19 Vaccines?
Clinical & Pharma Is RFK Jr. Spreading Misinformation on COVID-19 Vaccines?

The decision by Robert F. Kennedy Jr. to alter the United States' COVID-19 vaccination guidelines, especially regarding pregnant women and healthy children, has stirred considerable controversy. Announced on May 27, this move bypassed the conventional protocol of the Centers for Disease

BioNTech To Acquire CureVac, Boosting mRNA Cancer Therapies
Clinical & Pharma BioNTech To Acquire CureVac, Boosting mRNA Cancer Therapies

BioNTech, a leading force in the global pharmaceuticals industry, has embarked on a strategic acquisition of CureVac to solidify its position in mRNA-based cancer therapeutics. With this acquisition, the company looks to expand its capabilities beyond the notable success achieved with the COVID-19

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later